Results 31 to 40 of about 6,369 (156)
BMC Cancer, 2008 Background Patients with acute myeloid leukemia (AML) are often neutropenic as a result of their disease. Furthermore, these patients typically experience profound neutropenia following induction and/or consolidation chemotherapy and this may result in ...
Noga Stephen J +9 more
doaj +1 more source
Haematologica, 2007 Twenty-five elderly patients with oligoblastic acute myeloid leukemia (AML) received subcutaneous granulocyte colony-stimulating factor (filgrastim) in addition to supportive care.
Anna Maria Pelizzari +8 more
doaj +1 more source
Late-Onset Neutropenia in Long-Term Clozapine Use and Its Management Utilizing Prophylactic G-CSF
Case Reports in Psychiatry, 2021 This case outlines recurrent neutropenia after fourteen years of successful clozapine use. The patient has a diagnosis of treatment-resistant schizophrenia which has been complicated by sensitivity to side effects of haloperidol and past failure of ...
Eimear O’ Neill +3 more
doaj +1 more source
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background This study evaluated the efficacy and safety of mecapegfilgrastim for preventing immunochemotherapy‐induced neutropenia in treatment‐naive patients with diffuse large B‐cell lymphoma (DLBCL). Methods In this open‐label, multicenter exploratory trial, patients were randomized in a 2:1 ratio to receive mecapegfilgrastim or no ...
Jie Wang +15 more
wiley +1 more source
Italian Journal of Pediatrics, 2018 Background To compare the effect of xinruibai (Pegfilgrastim) and filgrastim injections on white blood cell and platelet (PLT) recovery, adverse events, post-operative complications, and cost effectiveness after allogeneic hematopoietic stem cell ...
Qixiang Ye, Hebi Jiang, Hua Jiang
doaj +1 more source
Acta Medica Indonesiana, 2022 Background: Myelosuppressive effects of chemotherapy for breast cancer treatment may trigger chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN). Filgrastim has been widely used as prophylaxis against CIN and FN.
Ami Ashariati +9 more
doaj +2 more sources
Cancer Medicine, Volume 15, Issue 5, May 2026.ABSTRACT Background Chemoimmunotherapy is widely used as the first‐line treatment for extensive‐stage small cell lung cancer (ES‐SCLC), but treatment options for second‐line have not changed. Amrubicin monotherapy is used as the standard treatment for relapsed SCLC, but since chemoimmunotherapy became an additional indication for ES‐SCLC, the efficacy ...
Kei Sonehara +16 more
wiley +1 more source
Drug Design, Development and Therapy, 2015 Liat Adar,1 Noa Avisar,1 Andreas Lammerich,2 Robert B Kleiman,3 Ofer Spiegelstein1 1R&D, Teva Pharmaceutical Industries Ltd, Netanya, Israel; 2Biosimilars Clinical Development, CPP Teva ratiopharm, Merckle GmbH, Ulm, Germany; 3Global Cardiology,
Adar L +4 more
doaj
The Current Use and Future Perspectives of Biosimilars in Pediatric Healthcare: A Narrative Review
Health Science Reports, Volume 9, Issue 5, May 2026.ABSTRACT Background and Aims The integration of biosimilars into pediatric healthcare represents a significant evolution in treatment accessibility and cost‐effectiveness. Biosimilars—biological products highly similar to already approved biologics, have emerged as promising alternatives for managing chronic and rare pediatric conditions, including ...
Zubaier Ahmed +6 more
wiley +1 more source
G‐CSF for Mobilizing CD34+ Cells in Individuals With SCD: A Word of Caution
American Journal of Hematology, Volume 101, Issue 6, Page 1178-1181, June 2026.
Akshay Sharma +17 more
wiley +1 more source